326 related articles for article (PubMed ID: 28444967)
1. Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
Li Y; Chen Y; Li J; Zhang Z; Huang C; Lian G; Yang K; Chen S; Lin Y; Wang L; Huang K; Zeng L
Cancer Sci; 2017 Jul; 108(7):1493-1503. PubMed ID: 28444967
[TBL] [Abstract][Full Text] [Related]
2. A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy.
Li J; Chen Y; Zeng L; Lian G; Chen S; Li Y; Yang K; Huang K
J Biomed Nanotechnol; 2016 Aug; 12(8):1654-66. PubMed ID: 29342344
[TBL] [Abstract][Full Text] [Related]
3. UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.
Lin L; Fan Y; Gao F; Jin L; Li D; Sun W; Li F; Qin P; Shi Q; Shi X; Du L
Theranostics; 2018; 8(7):1923-1939. PubMed ID: 29556365
[TBL] [Abstract][Full Text] [Related]
4. The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Yu H; Song H; Xiao J; Chen H; Jin X; Lin X; Pan B; Ji W
Biomed Pharmacother; 2017 Dec; 96():650-658. PubMed ID: 29035831
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
6. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
7. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.
Zhao Y; Zhao L; Ischenko I; Bao Q; Schwarz B; Nieß H; Wang Y; Renner A; Mysliwietz J; Jauch KW; Nelson PJ; Ellwart JW; Bruns CJ; Camaj P
Target Oncol; 2015 Dec; 10(4):535-48. PubMed ID: 25639539
[TBL] [Abstract][Full Text] [Related]
8. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
Lu Z; Su J; Li Z; Zhan Y; Ye D
Drug Dev Ind Pharm; 2017 Jan; 43(1):160-170. PubMed ID: 27553814
[TBL] [Abstract][Full Text] [Related]
10. Effective suppression of the Kirsten rat sarcoma viral oncogene in pancreatic tumor cells via targeted small interfering RNA delivery using nanoparticles.
Zeng L; Li J; Li J; Zhang Q; Qian C; Wu W; Lin Z; Liang J; Chen Y; Huang K
Pancreas; 2015 Mar; 44(2):250-9. PubMed ID: 25401377
[TBL] [Abstract][Full Text] [Related]
11. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.
Devulapally R; Foygel K; Sekar TV; Willmann JK; Paulmurugan R
ACS Appl Mater Interfaces; 2016 Dec; 8(49):33412-33422. PubMed ID: 27960411
[TBL] [Abstract][Full Text] [Related]
13. EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Mondal G; Almawash S; Chaudhary AK; Mahato RI
Mol Pharm; 2017 Sep; 14(9):3121-3133. PubMed ID: 28719220
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
[No Abstract] [Full Text] [Related]
15. Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer.
Uz M; Kalaga M; Pothuraju R; Ju J; Junker WM; Batra SK; Mallapragada S; Rachagani S
J Control Release; 2019 Jan; 294():237-246. PubMed ID: 30576747
[TBL] [Abstract][Full Text] [Related]
16. Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.
Cai H; Wang R; Guo X; Song M; Yan F; Ji B; Liu Y
Mol Pharm; 2021 Jul; 18(7):2495-2506. PubMed ID: 34078087
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
18. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
19. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
20. Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.
Lee GY; Qian WP; Wang L; Wang YA; Staley CA; Satpathy M; Nie S; Mao H; Yang L
ACS Nano; 2013 Mar; 7(3):2078-89. PubMed ID: 23402593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
